IL127315A - Texaphyrin-lipophilic molecule-vesicle complex and its different uses - Google Patents

Texaphyrin-lipophilic molecule-vesicle complex and its different uses

Info

Publication number
IL127315A
IL127315A IL12731597A IL12731597A IL127315A IL 127315 A IL127315 A IL 127315A IL 12731597 A IL12731597 A IL 12731597A IL 12731597 A IL12731597 A IL 12731597A IL 127315 A IL127315 A IL 127315A
Authority
IL
Israel
Prior art keywords
texaphyrin
lipophilic molecule
molecule conjugate
loaded
vesicle
Prior art date
Application number
IL12731597A
Other languages
English (en)
Other versions
IL127315A0 (en
Original Assignee
Pharmacyclics Inc
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Inc, Univ Texas filed Critical Pharmacyclics Inc
Publication of IL127315A0 publication Critical patent/IL127315A0/xx
Publication of IL127315A publication Critical patent/IL127315A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1896—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes not provided for elsewhere, e.g. cells, viruses, ghosts, red blood cells, virus capsides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T15/00—Three-dimensional [3D] image rendering
    • G06T15/10—Geometric effects
    • G06T15/20—Perspective computation
    • G06T15/205—Image-based rendering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Dispersion Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Cell Biology (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • Hematology (AREA)
  • Computing Systems (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Geometry (AREA)
  • General Physics & Mathematics (AREA)
  • Computer Graphics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Manufacture Of Macromolecular Shaped Articles (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL12731597A 1996-06-04 1997-06-04 Texaphyrin-lipophilic molecule-vesicle complex and its different uses IL127315A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65794796A 1996-06-04 1996-06-04
PCT/US1997/009501 WO1997046262A2 (en) 1996-06-04 1997-06-04 Membrane incorporation of texaphyrins

Publications (2)

Publication Number Publication Date
IL127315A0 IL127315A0 (en) 1999-09-22
IL127315A true IL127315A (en) 2003-05-29

Family

ID=24639282

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12731597A IL127315A (en) 1996-06-04 1997-06-04 Texaphyrin-lipophilic molecule-vesicle complex and its different uses

Country Status (12)

Country Link
EP (1) EP0954336B1 (de)
JP (1) JP2000512279A (de)
CN (1) CN1225591A (de)
AT (1) ATE260121T1 (de)
AU (1) AU727138B2 (de)
BR (1) BR9710685A (de)
CA (1) CA2257225A1 (de)
DE (1) DE69727833T2 (de)
IL (1) IL127315A (de)
NO (1) NO985645L (de)
NZ (1) NZ333072A (de)
WO (1) WO1997046262A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888997A (en) * 1994-04-14 1999-03-30 Pharmacyclics, Inc. Radiation sensitization using texaphyrins
US6375930B2 (en) 1996-06-04 2002-04-23 Board Of Regents, The University Of Texas System Membrane incorporation of texaphyrins
JP2002512594A (ja) * 1996-12-11 2002-04-23 ファーマサイクリックス,インコーポレイテッド 眼の診断および治療におけるテキサフィリンの使用
US6270749B1 (en) 1996-12-11 2001-08-07 Pharmacyclics, Inc. Use of Texaphyrin in ocular diagnosis and therapy
US6183727B1 (en) 1998-05-19 2001-02-06 Arizona Board Of Regents Use of long-wavelength electromagnetic radiation and photoprotective tumor localizing agents for diagnosis
US6454789B1 (en) 1999-01-15 2002-09-24 Light Science Corporation Patient portable device for photodynamic therapy
US6602274B1 (en) 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy
WO2000041726A2 (en) * 1999-01-15 2000-07-20 Light Sciences Corporation Noninvasive vascular therapy
EP1206288B1 (de) * 1999-08-02 2007-01-10 The Regents Of The University Of Michigan Zielgerichtete fiberlose radiative effektoren
US6351663B1 (en) 1999-09-10 2002-02-26 Akorn, Inc. Methods for diagnosing and treating conditions associated with abnormal vasculature using fluorescent dye angiography and dye-enhanced photocoagulation
US6944493B2 (en) 1999-09-10 2005-09-13 Akora, Inc. Indocyanine green (ICG) compositions and related methods of use
AU7106400A (en) * 1999-09-10 2001-04-10 Akorn, Inc. Fluorescent dye angiography and dye-enhanced photocoagulation
US6443976B1 (en) 1999-11-30 2002-09-03 Akorn, Inc. Methods for treating conditions and illnesses associated with abnormal vasculature
US6319273B1 (en) * 1999-12-16 2001-11-20 Light Sciences Corporation Illuminating device for treating eye disease
CA2395567A1 (en) 2000-01-12 2001-07-19 Light Sciences Corporation Novel treatment for eye disease
US7112671B2 (en) 2000-08-30 2006-09-26 Pharmacyclics, Inc. Non-symmetric tripyrranes in the synthesis of novel macrocycles
US6638924B2 (en) 2000-08-30 2003-10-28 Pharmacyclics, Inc. Metallotexaphyrin derivatives
US7449454B2 (en) 2000-08-30 2008-11-11 Pharmacyclics, Inc. Metallotexaphyrin derivatives
JP2007512221A (ja) * 2003-11-21 2007-05-17 富士フイルム株式会社 疎水性キレート化合物を含有するリポソームを含む造影剤
US20070072838A1 (en) 2005-09-26 2007-03-29 Pharmacyclics, Inc. High-purity texaphyrin metal complexes
US10729792B2 (en) 2015-04-17 2020-08-04 University Health Network Texaphyrin-phospholipid conjugates and methods of preparing same
CN111265674A (zh) * 2020-03-24 2020-06-12 浙江大学医学院附属第四医院(浙江省义乌医院、浙江大学医学院附属第四医院医共体) 一种造影剂、造影剂的制备方法及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599923A (en) * 1989-03-06 1997-02-04 Board Of Regents, University Of Tx Texaphyrin metal complexes having improved functionalization
US5457183A (en) * 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US5120411A (en) * 1989-12-21 1992-06-09 Board Of Regents, The University Of Texas System Photodynamic activity of sapphyrins
US5756726A (en) * 1995-06-02 1998-05-26 Pharmacyclics, Inc. Methods of producing singlet oxygen using compounds having improved functionalization

Also Published As

Publication number Publication date
EP0954336A2 (de) 1999-11-10
BR9710685A (pt) 2000-01-11
AU727138B2 (en) 2000-12-07
WO1997046262A3 (en) 1998-03-12
WO1997046262A2 (en) 1997-12-11
DE69727833D1 (de) 2004-04-01
JP2000512279A (ja) 2000-09-19
EP0954336B1 (de) 2004-02-25
NZ333072A (en) 2000-06-23
NO985645L (no) 1999-02-03
NO985645D0 (no) 1998-12-03
IL127315A0 (en) 1999-09-22
ATE260121T1 (de) 2004-03-15
AU3226497A (en) 1998-01-05
CA2257225A1 (en) 1997-12-11
DE69727833T2 (de) 2005-01-13
CN1225591A (zh) 1999-08-11

Similar Documents

Publication Publication Date Title
IL127315A0 (en) Membrane incorporation of texaphyrins
DE69715449T2 (de) Druckvermittelte, intrazellulaere verabreichung von molekuelen oder mikropartikeln
ATE99544T1 (de) Liposomale radiologische kontrastmittel.
SG43886A1 (en) Hepatobiliary nmr contrast agents
Kjønniksen et al. Nude rat model for studying metastasis of human tumor cells to bone and bone marrow
Berthezene et al. Differentiation of alveolitis and pulmonary fibrosis with a macromolecular MR imaging contrast agent.
Green et al. Human central nervous system and plasma pharmacology of mitoxantrone
DE59600683D1 (de) Verwendung von Trospiumchlorid zur Herstellung eines Arzneimittels zur Behandlung von Blasenkrankheiten
Graeber et al. Elevated levels of peripheral serum creatine phosphokinase with strangulated small bowel obstruction
Karakousis et al. Modes of regional chemotherapy
JPH05501856A (ja) 脳及び筋肉組織傷害による浮腫の治療剤
Stewart et al. The treatment of patients with interstitial cystitis, with special reference to intravesical DMSO
Espert et al. Evaluation of risk of splenosis during laparoscopic splenectomy in rat model
Elger et al. MRI study on delayed ancrod therapy of focal cerebral ischaemia in rats
WO1997033620A2 (de) Verbindungen zur behandlung von tumoren
RU2192817C2 (ru) Способ лечения частичной атрофии зрительного нерва
DE102005055469A1 (de) Ganzkörper-Hyperthermie-Anwendung, in einer Spezialwanne, ausgestattet mit Heilströmen in speziellen aufbereitetem Wasser zur gleichzeitiger Unterwasserschweißausscheidung für den menschlichen Körper
Tian et al. Effect on myocardial perfusion of simultaneous delivery of cardioplegic solution through a single coronary artery and the coronary sinus
SU1717105A1 (ru) Способ рентгенологического исследовани желчевывод щих путей
Cook et al. Highly substituted phthalocyanine derivatives as potential photosensitizers for photodynamic therapy of tumors
Nuernberg et al. Anti-inflammatory effects and disposition of S-and R-flurbiprofen in the rat
Ushiyama et al. Physiological Effects of Continuous Whole-Body Exposure to Extremely Low Frequency Electromagnetic Fields With or Without Transient Magnetic Fields on Cerebral Microcirculation in Mice With Brain Tumors
Zhang et al. Adriamycin thermotherapy through hepatic artery for model of VX2 carcinoma in rabbit liver
Martásek et al. Porphyrinogens in plasma
Feder Tick bite prevention: get naked?

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees